5/17/2023 0 Comments Recordpad 5.35206010012601 Diabetes mellitus Diseases 0.000 claims description 31.XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 32.BPRHUIZQVSMCRT-VEUZHWNKSA-N Rosuvastatin Chemical compound BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 38.150000003626 triacylglycerols Chemical class 0.000 claims description 45.125000003275 alpha amino acid group Chemical group 0.000 claims description 55.OLNTVTPDXPETLC-XPWALMASSA-N Ezetimibe Chemical compound OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims description 61.238000002560 therapeutic procedure Methods 0.000 claims description 65.150000002632 lipids Chemical class 0.000 claims description 67.238000006722 reduction reaction Methods 0.000 claims description 70.239000003795 chemical substances by application Substances 0.000 claims description 81.239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 99.208000004981 Coronary Disease Diseases 0.000 claims description 159.231100000682 maximum tolerated dose Toxicity 0.000 claims abstract description 62. 230000002401 inhibitory effect Effects 0.000 claims abstract description 76.239000003112 inhibitor Substances 0.000 claims abstract description 76.201000008739 coronary artery disease Diseases 0.000 claims abstract description 162.108090001123 antibodies Proteins 0.000 claims abstract description 273.102000004965 antibodies Human genes 0.000 claims abstract description 273.230000000271 cardiovascular Effects 0.000 title abstract description 56.208000009576 Hypercholesterolemia Diseases 0.000 title claims abstract description 55.Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from US201462025371P external-priority Application filed by First Drugmaker Of Regenerating, Sanofi SA filed Critical First Drugmaker Of Regenerating Priority to CN202111397525.XA priority Critical patent/CN114306592A/en Publication of CN107106678A publication Critical patent/CN107106678A/en Status Pending legal-status Critical Current Links Original Assignee First Drugmaker Of Regenerating Sanofi SA Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) 施韦默尔吉普 Current Assignee (The listed assignees may be inaccurate.Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Pending Application number CN201580049703.6A Other languages Chinese ( zh) Google Patents Method for treating the high cardiovascular risk patient with hypercholesterolemiaĭownload PDF Info Publication number CN107106678A CN107106678A CN201580049703.6A CN201580049703A CN107106678A CN 107106678 A CN107106678 A CN 107106678A CN 201580049703 A CN201580049703 A CN 201580049703A CN 107106678 A CN107106678 A CN 107106678A Authority CN China Prior art keywords patient antibody ldl treatment pcsk9 Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google Patents CN107106678A - Method for treating the high cardiovascular risk patient with hypercholesterolemia System-wide hotkeys allow keyboard control over recording while working in other programsįind and Play recordings by format, date, duration and size.CN107106678A - Method for treating the high cardiovascular risk patient with hypercholesterolemia Recordings can be burned directly to CD using Express Burn Record only when you are speaking with voice activated recording Save recordings to your hard drive in wav, mp3 or aiff format Record sound, voice, notes, music or any other audio Using RecordPad, you can quickly and easily record audio notes, messages or announcements in either wav or mp3. Recording with a computer has never been easier. RecordPad is ideal for recording voice and other audio to add to digital presentations, creating an audio book, or for simply recording a message.
0 Comments
Leave a Reply. |